Amelia Insa

15.8k total citations
63 papers, 1.5k citations indexed

About

Amelia Insa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Amelia Insa has authored 63 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Amelia Insa's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Cancer Genomics and Diagnostics (12 papers). Amelia Insa is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Cancer Genomics and Diagnostics (12 papers). Amelia Insa collaborates with scholars based in Spain, Germany and France. Amelia Insa's co-authors include Eduardo Nagore, Aňa Lluch, J Garcı́a-Conde, Margarita Majem, Ángel Martínez-Agulló, Isabel Marugán, Felipe Prósper, Enric Carcereny, Noemı́ Reguart and Mariano Provencio and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Amelia Insa

57 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amelia Insa Spain	18	1.1k	697	317	277	249	63	1.5k
Barbara Melosky Canada	28	1.3k 1.2×	1.1k 1.6×	388 1.2×	334 1.2×	101 0.4×	116	2.0k
Pınar Saip Türkiye	21	606 0.6×	520 0.7×	288 0.9×	354 1.3×	87 0.3×	115	1.6k
Isabel Chirivella Spain	16	1.1k 1.0×	453 0.6×	246 0.8×	254 0.9×	98 0.4×	53	1.5k
Daniel Vorobiof South Africa	18	938 0.9×	390 0.6×	153 0.5×	300 1.1×	98 0.4×	61	1.6k
Per‐Ebbe Jönsson Sweden	20	927 0.9×	434 0.6×	239 0.8×	270 1.0×	161 0.6×	35	1.5k
R. Largillier France	14	940 0.9×	334 0.5×	162 0.5×	527 1.9×	130 0.5×	47	1.5k
Editta Baldini Italy	21	1.1k 1.0×	470 0.7×	319 1.0×	513 1.9×	53 0.2×	83	1.5k
Nobuyuki Mizunuma Japan	23	1.5k 1.4×	530 0.8×	506 1.6×	367 1.3×	68 0.3×	133	2.0k
Alessandra Ravaioli Italy	19	913 0.8×	533 0.8×	210 0.7×	209 0.8×	41 0.2×	107	1.3k
Miso Kim South Korea	25	1.2k 1.1×	710 1.0×	292 0.9×	208 0.8×	55 0.2×	87	1.7k

Countries citing papers authored by Amelia Insa

Since Specialization

Citations

This map shows the geographic impact of Amelia Insa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amelia Insa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amelia Insa more than expected).

Fields of papers citing papers by Amelia Insa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amelia Insa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amelia Insa. The network helps show where Amelia Insa may publish in the future.

Co-authorship network of co-authors of Amelia Insa

This figure shows the co-authorship network connecting the top 25 collaborators of Amelia Insa. A scholar is included among the top collaborators of Amelia Insa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amelia Insa. Amelia Insa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nadal, Ernest, Bartomeu Massutí, Aránzazu García‐Grande, et al.. (2025). Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). OncoImmunology. 14(1). 2513109–2513109.

Nadal, Ernest, Paloma Martín-Martorell, José Carlos Benítez, et al.. (2025). Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Lung Cancer. 203. 108545–108545.

Insa, Amelia, et al.. (2025). Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis. Lung Cancer. 202. 108464–108464.

Cascone, Tina, Laura Bonanno, M. A. Lieberman, et al.. (2024). PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC. Journal of Thoracic Oncology. 19(10). S1–S2. 6 indexed citations

Martín-Martorell, Paloma, Francisco Aparisi, María José Domper-Arnal, et al.. (2024). A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. Clinical & Translational Oncology. 27(6). 2568–2578. 1 indexed citations

Castro, Javier de, Amelia Insa, Roberto Collado‐Borrell, et al.. (2023). Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 23(1). 69–69. 6 indexed citations

Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations

Riudavets, Mariona, Joaquim Bosch‐Barrera, Luis Cabezón‐Gutiérrez, et al.. (2021). Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 23(12). 2560–2567. 7 indexed citations

Insa, Amelia, Paloma Martín-Martorell, Raimondo Di Liello, et al.. (2021). Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Critical Reviews in Oncology/Hematology. 169. 103538–103538. 23 indexed citations

10.

Paredes, Alfredo, Teresa Morán, Bartomeu Massutí, et al.. (2020). ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Revista Española de Patología. 53(3). 140–148. 2 indexed citations

11.

Gambardella, Valentina, Amelia Insa, Juan Miguel Cejalvo, & Andrés Cervantes. (2020). In the literature: December 2019. ESMO Open. 5(1). e000642–e000642.

12.

Garde, J., Paloma Martín-Martorell, Carmen Salvador Coloma, et al.. (2018). Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clinical & Translational Oncology. 20(8). 1072–1079. 46 indexed citations

13.

Majem, Margarita, Óscar Juan, Amelia Insa, et al.. (2018). SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clinical & Translational Oncology. 21(1). 3–17. 127 indexed citations

14.

Martín-Martorell, Paloma, Marisol Huerta, Rosario Abellán, et al.. (2017). Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. Clinical Lung Cancer. 18(6). e395–e402. 31 indexed citations

15.

Reguart, Noemı́, Rafael Rosell, Felipe Cardenal, et al.. (2014). Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 84(2). 161–167. 72 indexed citations

16.

Morán, Teresa, Enriqueta Felip, Vicki L. Keedy, et al.. (2014). Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Experimental Hematology and Oncology. 3(1). 26–26. 27 indexed citations

17.

Martín-Martorell, Paloma, et al.. (2007). Nonbacterial thrombotic endocarditis associated with lung adenocarcinoma. Clinical & Translational Oncology. 9(11). 744–746. 7 indexed citations

18.

Nagore, Eduardo, Dolores Planelles, José M. Millán, et al.. (2002). Molecular Genetic Analysis of HLA-DR and -DQ Alleles in Spanish Patients with Melanoma. Acta Dermato Venereologica. 82(2). 90–93. 6 indexed citations

19.

Nagore, Eduardo, et al.. (2000). Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) Syndrome. American Journal of Clinical Dermatology. 1(4). 225–234. 225 indexed citations

20.

Martín, M., Aňa Lluch, Antonio Casado, et al.. (2000). Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. Annals of Oncology. 11(1). 85–90. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact